Apellis Pharmaceuticals, Inc. (APLS) Reaches $23.49 After 7.00% Down Move; Last Week Illinois Tool Works Inc. (ITW) Coverage

January 7, 2018 - By Adrian Erickson

The stock of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a huge mover today! The stock decreased 5.81% or $1.45 during the last trading session, reaching $23.49. About 100,243 shares traded. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since January 7, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 8 months negative chart setup for the $1.18 billion company. It was reported on Jan, 7 by Barchart.com. We have $21.85 PT which if reached, will make NASDAQ:APLS worth $82.74M less.

Among 19 analysts covering Illinois Tool Works Inc (NYSE:ITW), 8 have Buy rating, 0 Sell and 11 Hold. Therefore 42% are positive. Illinois Tool Works Inc had 71 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Friday, February 17 by Goldman Sachs. On Monday, August 14 the stock rating was maintained by Stifel Nicolaus with “Hold”. Stifel Nicolaus maintained the stock with “Hold” rating in Tuesday, July 4 report. BMO Capital Markets maintained it with “Buy” rating and $145 target in Friday, April 21 report. The stock of Illinois Tool Works Inc. (NYSE:ITW) has “Hold” rating given on Friday, October 20 by RBC Capital Markets. Morgan Stanley maintained the shares of ITW in report on Thursday, April 21 with “Equal-Weight” rating. The company was maintained on Friday, September 15 by Stifel Nicolaus. The rating was downgraded by Goldman Sachs on Monday, November 21 to “Neutral”. The firm earned “Neutral” rating on Thursday, June 23 by Robert W. Baird. The rating was maintained by Argus Research with “Buy” on Tuesday, October 24. See Illinois Tool Works Inc. (NYSE:ITW) latest ratings:

04/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $180.0 Downgrade
11/12/2017 Broker: Bank of America Rating: Buy New Target: $190.0 Initiate
04/12/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $176.0 Maintain
04/12/2017 Broker: RBC Capital Markets Rating: Hold New Target: $166.0 Maintain
04/12/2017 Broker: Wells Fargo Rating: Buy New Target: $190.0 Maintain
03/12/2017 Broker: Robert W. Baird Rating: Hold New Target: $160.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $155.0 Maintain
24/10/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $147 New Target: $151 Maintain
24/10/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $160 New Target: $165 Maintain
24/10/2017 Broker: Credit Suisse Rating: Neutral Old Target: $142 New Target: $140 Maintain

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.18 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

The stock decreased 0.07% or $0.12 during the last trading session, reaching $166.03. About 1.44 million shares traded or 27.80% up from the average. Illinois Tool Works Inc. (NYSE:ITW) has risen 33.32% since January 7, 2017 and is uptrending. It has outperformed by 16.62% the S&P500.

Illinois Tool Works Inc. manufactures and sells industrial products and equipment worldwide. The company has market cap of $56.88 billion. It operates through seven divisions: Automotive OEM; Test & Measurement and Electronics; Food Equipment; Polymers & Fluids; Welding; Construction Products; and Specialty Products. It has a 25.47 P/E ratio. The Automotive OEM segment produces plastic and metal components, fasteners, and assemblies for automotive-related applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>